Status | Study |
Withdrawn |
Study Name: Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer Condition: Fallopian Tube Neoplasms Ovarian Cancer Date: 2010-05-21 Interventions: Drug: Gemcitabine/Bevacizumab Gemcitabine: IV, days 1,8, a |
Completed |
Study Name: A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2008-06-12 Interventions: Drug: doxorubicin HCL liposome; bevacizumab; carboplatin 30 mg/m2 by intravenous infusion Day 1 of each |
Terminated |
Study Name: Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2007-03-07 Interventions: Drug: Vandetanib 300 mg daily dose, 28 day cycle Oth |
Completed |
Study Name: Pharmacogenomics of Paclitaxel in Ovarian Cancer Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2006-12-21 |
Terminated |
Study Name: ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Condition: Fallopian Tube Neoplasms Peritoneal Neoplasms Date: 2006-12-01 Interventions: Drug: ABI-007 80mg/m^2 to 150m |
Completed |
Study Name: Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") Condition: Ovarian Cancer Fallopian Tube Neoplasms Date: 2006-10-19 Interventions: Drug: enzastaurin 1125 mg load |
Completed |
Study Name: Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Condition: Adenocarcinoma Ovarian Neoplasms Fal Date: 2006-06-14 Interventions: Procedure: MiCK Assay Physician determined treatment |
Completed |
Study Name: Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients Condition: Ovarian Cancer Fallopian Tube Neoplasms Date: 2005-09-12 Interventions: Biological: anti-EpCAM x anti-CD3 (removab) |
Completed |
Study Name: OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2005-05-27 Interventions: Drug: Neoadjuvant chemotherapy (Paclitaxel and Carboplatin) |
Completed |
Study Name: Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response Condition: Ovarian Cancer Fallopian Tube Neoplasms Date: 2005-02-10 Interventions: Biological: ACA 125 |